Novo nordisk share price

The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. This browser is no longer supported at MarketWatch. For the best MarketWatch, novo nordisk share price.

Research shows urgent need for policies to encourage weight loss and cut disease risk. The EU is missing out on trillions of euros of capital for its businesses. German pharma group finds no unexpected side effects during trial, including at higher doses. Financial Times Close. Search the FT Search. Show more World link World. Show more US link US.

Novo nordisk share price

In order to secure liquidity for both the Novo Nordisk B shares and American Depositary Receipts ADRs and bring price levels in line with market practice for especially the ADRs, the Board of Directors has decided to split the trading units in a two-for-one ratio. After the split, the total number of A shares of nom. DKK 0. Each A-share of nom. DKK 0,10 carries votes. Consequently, the total number of votes relating to the A shares is ,,, votes. After the split, the total number of B shares of nom. Each B-share of nom. DKK 0,10 carries 10 votes. Consequently, the total number of votes relating to the B shares is 34,,, votes. Please find the company announcement regarding the stock split here. Barclays Capital Emily Field, emily.

Pfizer Inc. IBEX Show more Markets link Markets.

.

Investor optimism was driven by Novo Nordisk's reveal on Thursday that a Phase I trial of the pill version of the experimental drug amycretin showed participants lost The Danish drug manufacturer is riding a wave of investor enthusiasm for GLP-1 obesity drugs. JPMorgan's analysts said this week that retail traders had shifted focus to pharma stocks , dumping most Magnificent Seven names in the last week. Read next. Search markets. My Watchlist. Business Insider logo. Close icon Two crossed lines that form an 'X'. It indicates a way to close an interaction, or dismiss a notification. Yuheng Zhan.

Novo nordisk share price

Novo Nordisk, of anti-obesity drug Wegovy fame, reveals encouraging initial trial data for new weight loss drug that could potentially overtake Wegovy. Pharmaceutical giant Novo Nordisk has recently overtaken electric vehicle maker Tesla, in terms of market valuation, following upbeat initial trial data for a new obesity drug. Following the launch of Wegovy in June , Novo Nordisk has established itself as a leader in the weight-loss drug sector, making the news of a potential new drug even more highly anticipated. A GLP-1 agonist drug, Wegovy was initially designed to treat type 2 diabetes.

Elden ring best strength weapon

Annual Report. How can we help? Last Updated: Mar 1, p. Quigley ln. ET by Philip van Doorn. They Could Keep Climbing. Add Tickers. IBEX Save Clear. DKK 0. Chrome Safari Firefox Edge. Show more Companies link Companies. Stoxx Please find the company announcement regarding the stock split here.

Drugmaker releases promising trial results for a pill and expects to enter China this year.

DKK 0. Chrome Safari Firefox Edge. The EU is missing out on trillions of euros of capital for its businesses. Symbols Loading Intron Health Naresh Chouhan, naresh intronhealthresearch. DKK 0,10 carries votes. Each B-share of nom. Log in to see them here or sign up to get started. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. Actions Add to watchlist Add to portfolio Add an alert. German pharma group finds no unexpected side effects during trial, including at higher doses. Search Clear. All content on FT.